Digest Network Come funziona
Network
/
Società
Im
Non verificato

ImmunityBio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

78 comunicati stampa

Guarda tutti i comunicati
10/08/2026
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Oncologia
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
04/08/2026
Mercato azionario
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
29/07/2026
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
01/06/2026
Eventi
Fiere
Industria
Farmaceutica
Salute
Oncologia
Medicina - Varie
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
22/05/2026
Eventi
Industria
Analisi di mercato
Associazioni/Professionisti
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Sanità
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
22/05/2026
Farmaceutica
Salute
Oncologia
Medicina - Varie
Eventi
Industria
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
20/05/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Industria
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
19/05/2026
Industria
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
18/05/2026
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Industria
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
16/05/2026
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Web e Social Network
Mercato del lavoro
Eventi
Industria
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0